
About Sonnet BioTherapeutics
Sonnet BioTherapeutics is a publicly listed company based in Princeton (United States) founded in 2011 by Pankaj Mohan. Immunotherapies for cancer treatment are developed using proprietary FHAB technology. Sonnet BioTherapeutics has raised $750 thousand across 4 funding rounds. The company has 13 employees. Its chief executive, as recorded, is Pankaj Mohan. Sonnet BioTherapeutics offers products and services including SON-1010, SON-1210, and SON-080. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Sonnet BioTherapeutics, Inc. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Sonnet BioTherapeutics was founded in 2011 and is based in Princeton, United States. The company operates in the biotechnology sector, focusing on immunotherapies for cancer treatment. Proprietary FHAB technology is utilized to develop targeted biologic drugs featuring single- or bi-specific mechanisms. The lead compound, SON-1010, is advanced for solid tumors, with operations centered on innovative biologic drug creation.
- Headquarters Princeton, United States
- Employees 13
- Founders Pankaj Mohan
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website sonnetbio.com
- Social LinkedIn X
- Legal Name Sonnet Biotherapeutics Holdings, Inc.
- Annual Revenue$18.63 K (USD)-87.4as on Sep 30, 2024
- Net Profit-$7.44 M (USD)60.51as on Sep 30, 2024
- EBITDA-$11.75 M (USD)36.24as on Sep 30, 2024
- Total Equity Funding$750K (USD)
in 4 rounds
- Latest Funding Round$3.92M (USD), Post-IPO
Dec 2024
- Employee Count13
Products & Services of Sonnet BioTherapeutics
Sonnet BioTherapeutics offers a comprehensive portfolio of products and services, including SON-1010, SON-1210, and SON-080.
Cytokine-derived drug for immuno-oncology tumor treatment.
Biologic for enhanced immuno-oncology applications.
Cytokine-based therapeutic in clinical pipeline.
Funding Insights of Sonnet BioTherapeutics
Sonnet BioTherapeutics has successfully raised a total of $750K across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.92 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $750,000
- Total Rounds 4
- Last Round Post-IPO β $3.92M
- First Round $750,000
(May 2019)
All 4 funding rounds of Sonnet BioTherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $3.92M | Post-IPO | β | β | β |
| Jul 2023 | $2.25M | Post-IPO | β | β | β |
| Aug 2020 | $10.5M | Post-IPO | β | β | β |
| May 2019 | $750,000 | Seed | β | β | β |
People of Sonnet BioTherapeutics
14 people are tracked at Sonnet BioTherapeutics (4 in leadership, 9 in board & advisors, 1 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Pankaj Mohan | Founder & CEO & Chairman | Leadership |
Susan Dexter | Chief Technical Officer | Leadership |
John K. Cini | Chief Scientific Officer & Co Founder | Leadership |
Stephen J. McAndrew | Chief Business Officer | Leadership |
Jason Bock | Advisor | Board & advisors |
Hossein Borghaei | Advisor | Board & advisors |
Nailesh Bhatt | Director | Board & advisors |
Guido Cavaletti | Advisor | Board & advisors |
Donald Griffith | Director | Board & advisors |
Albert Dyrness | Director | Board & advisors |
Raghu Rao | Director | Board & advisors |
Robert Wenham | Advisor | Board & advisors |
Lori McNeill | Director | Board & advisors |
Kal Ghosh | Executive Administrative Assistant | Team |
Complete people profiles for Sonnet BioTherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sonnet BioTherapeutics
Sonnet BioTherapeutics is a publicly listed company on the NASDAQ with ticker symbol SONN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Apr 2020
- Listed onNASDAQ: SONN
- Listed entitySonnet BioTherapeutics Holdings, Inc.
- Exchange sectorHealth technology
- ISINUS83548R4020
- Share price$1.26 (-59.35% on the day) · 2025-12-03
- Market capitalisation$8.9M
- EPS (diluted, trailing year)$-8.22
- Volume (last session)10,456,153
- Analyst consensusStrong buy
Financials of Sonnet BioTherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $18,630 | -$7.4M | -$11.8M |
| 2023 | $147,810 | -$18.8M | -$18.4M |
| 2022 | $349,940 | -$29.7M | -$28.6M |
| 2021 | $483,630 | -$25.0M | -$25.0M |
| 2020 | -$24.3M | -$17.4M |
Detailed financial statements for Sonnet BioTherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Sonnet BioTherapeutics
4 dated milestones of Sonnet BioTherapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Sonnet BioTherapeutics is founded.
- Funding First funding round of $750K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $3.9M.
Competitors of Sonnet BioTherapeutics
Sonnet BioTherapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Sonnet BioTherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sonnet BioTherapeutics
The website of Sonnet BioTherapeutics (sonnetbio.com) receives about 10K visits a month.
- Monthly visits10K
▼ 22.2% vs previous month
Websites whose visitors overlap most with Sonnet BioTherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| synbio-tech.com | 100% | 21.9K | #1,181,176 | View details | |
| otradi.org | 98% | #8,709,976 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Sonnet BioTherapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sonnet Biotherapeutics
Complete news archive for Sonnet BioTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sonnet BioTherapeutics
Sonnet BioTherapeutics was founded in 2011 and raised its 1st funding round 8 years after it was founded.
Sonnet BioTherapeutics is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Pankaj Mohan is the CEO of Sonnet BioTherapeutics, as recorded in our data. They have also founded this company.
Sonnet BioTherapeutics is a funded company, having raised a total of $750K across 4 funding rounds to date. The company's 1st funding round was a Seed of $750K, raised on May 2019.
Sonnet BioTherapeutics has 13 employees.
Annual revenue of Sonnet BioTherapeutics is $18.63K as on Sep 30, 2024.
Sonnet BioTherapeutics was founded in 2011 and is based in Princeton, United States. The company operates in the biotechnology sector, focusing on immunotherapies for cancer treatment. Proprietary FHAB technology is utilized to develop targeted biologic drugs featuring single- or bi-specific mechanisms. The lead compound, SON-1010, is advanced for solid tumors, with operations centered on innovative biologic drug creation.
Sonnet BioTherapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
Sonnet BioTherapeutics offers SON-1010, SON-1210, and SON-080.
Yes, Sonnet BioTherapeutics is publicly traded on NASDAQ under the ticker symbol SONN.
Sonnet BioTherapeutics operates through Sonnet Biotherapeutics, Inc..
